Hillstream Biopharma (CNTN) Stock Price, News & Analysis

Company Overview

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

Key Stats

• Today's Range: $1.83 to $1.95
• 50-Day Range: $1.85 to $3.54
• 52-Week Range: $1.08 to $9.08
• Volume: 464,693 shs
• Average Volume: 856,667 shs
• Market Capitalization: $144.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Hillstream Biopharma Stock Analysis - MarketRank™

Hillstream Biopharma scored higher than 9% of companies evaluated by MarketBeat, and ranked 803rd out of 838 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Hillstream Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Hillstream Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hillstream Biopharma is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hillstream Biopharma is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hillstream Biopharma has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.43% of the float of Hillstream Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Hillstream Biopharma has a short interest ratio ("days to cover") of 11.84, which indicates bearish sentiment.

Change versus previous month

Short interest in Hillstream Biopharma has recently increased by 11.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hillstream Biopharma does not currently pay a dividend.

Dividend Growth

Hillstream Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.89

News Sentiment

Hillstream Biopharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Finance companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Hillstream Biopharma this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Hillstream Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hillstream Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $343,825.00 in company stock.

Percentage Held by Insiders

3.34% of the stock of Hillstream Biopharma is held by insiders.

Percentage Held by Institutions

1.16% of the stock of Hillstream Biopharma is held by institutions.

Company Calendar

• Today: 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Financial Services
• Sub-Industry: Multi-Sector Holdings
• Current Symbol: NASDAQ:CNTN
• CIK: 1861657
• Web: N/A
• Phone: (302) 743-2995
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.50%
• Return on Assets: -24.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 37.76
• Quick Ratio: 37.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.92 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 77,123,000
• Free Float: 74,547,000
• Market Cap: $144.22 million
• Optionable: N/A
• Beta: 1.45